Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC

A. S. Sarkis, D. F. Bajorin, V. E. Reuter, H. W. Herr, G. Netto, Z. F. Zhang -, P. K. Schultz, C. Cordon-Cardo, H. I. Scher

Research output: Contribution to journalArticle

Abstract

Purpose: This study sought to examine the prognostic role nuclear overexpression in muscle-invasive bladder cancer because of its correlation with progression of superficial bladder cancer. Patients and Methods: Ninety of 111 patients treated with neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) with a median follow-up duration of 5.8 years were evaluated. p53 nuclear overexpression was determined by immunohistochemistry on deparaffinized tissue sections. Patients were stratified into two groups according to the percent of tumor cells with positive nuclear reactivity. Overexpression was defined as tumors with ≥ 20% cells with positive nuclear reactivity and nonoverexpression as tumors with less than 20% reactivity. Results: Nuclear overexpression was observed in 47 patients and nonoverexpression in 43 patients. Patients whose tumors had p53 overexpression had a significantly higher proportion of cancer deaths. A multivariate analysis that evaluated the pretreatment variables p53 nuclear overexpression, age, sex, palpable mass, prechemotherapy tumor stage, performance status, ureteral obstruction, tumor size, multifocality, and grade showed that p53 overexpression had independent significance for survival (P = .001; relative risk ratio, 3.1). The impact of p53 overexpression on survival was predominantly in T2 and T3a tumors. Long-term survival was evident in seven of 17 patients (41%) with p53 overexpression versus 20 of 26 (77%) in whom p53 was not overexpressed (P = .007). Conclusion: p53 nuclear overexpression has independent prognostic value for survival in patients with invasive bladder cancer treated with neoadjuvant chemotherapy.

Original languageEnglish (US)
Pages (from-to)1384-1390
Number of pages7
JournalJournal of Clinical Oncology
Volume13
Issue number6
StatePublished - 1995
Externally publishedYes

Fingerprint

Vinblastine
Urinary Bladder Neoplasms
Methotrexate
Doxorubicin
Cisplatin
Neoplasms
Survival
Ureteral Obstruction
Multivariate Analysis
Immunohistochemistry
Odds Ratio
Drug Therapy
Muscles

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sarkis, A. S., Bajorin, D. F., Reuter, V. E., Herr, H. W., Netto, G., Zhang -, Z. F., ... Scher, H. I. (1995). Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. Journal of Clinical Oncology, 13(6), 1384-1390.

Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. / Sarkis, A. S.; Bajorin, D. F.; Reuter, V. E.; Herr, H. W.; Netto, G.; Zhang -, Z. F.; Schultz, P. K.; Cordon-Cardo, C.; Scher, H. I.

In: Journal of Clinical Oncology, Vol. 13, No. 6, 1995, p. 1384-1390.

Research output: Contribution to journalArticle

Sarkis, AS, Bajorin, DF, Reuter, VE, Herr, HW, Netto, G, Zhang -, ZF, Schultz, PK, Cordon-Cardo, C & Scher, HI 1995, 'Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC', Journal of Clinical Oncology, vol. 13, no. 6, pp. 1384-1390.
Sarkis, A. S. ; Bajorin, D. F. ; Reuter, V. E. ; Herr, H. W. ; Netto, G. ; Zhang -, Z. F. ; Schultz, P. K. ; Cordon-Cardo, C. ; Scher, H. I. / Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 6. pp. 1384-1390.
@article{bb11cd85d8d94406ad9c308c74adabf3,
title = "Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC",
abstract = "Purpose: This study sought to examine the prognostic role nuclear overexpression in muscle-invasive bladder cancer because of its correlation with progression of superficial bladder cancer. Patients and Methods: Ninety of 111 patients treated with neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) with a median follow-up duration of 5.8 years were evaluated. p53 nuclear overexpression was determined by immunohistochemistry on deparaffinized tissue sections. Patients were stratified into two groups according to the percent of tumor cells with positive nuclear reactivity. Overexpression was defined as tumors with ≥ 20{\%} cells with positive nuclear reactivity and nonoverexpression as tumors with less than 20{\%} reactivity. Results: Nuclear overexpression was observed in 47 patients and nonoverexpression in 43 patients. Patients whose tumors had p53 overexpression had a significantly higher proportion of cancer deaths. A multivariate analysis that evaluated the pretreatment variables p53 nuclear overexpression, age, sex, palpable mass, prechemotherapy tumor stage, performance status, ureteral obstruction, tumor size, multifocality, and grade showed that p53 overexpression had independent significance for survival (P = .001; relative risk ratio, 3.1). The impact of p53 overexpression on survival was predominantly in T2 and T3a tumors. Long-term survival was evident in seven of 17 patients (41{\%}) with p53 overexpression versus 20 of 26 (77{\%}) in whom p53 was not overexpressed (P = .007). Conclusion: p53 nuclear overexpression has independent prognostic value for survival in patients with invasive bladder cancer treated with neoadjuvant chemotherapy.",
author = "Sarkis, {A. S.} and Bajorin, {D. F.} and Reuter, {V. E.} and Herr, {H. W.} and G. Netto and {Zhang -}, {Z. F.} and Schultz, {P. K.} and C. Cordon-Cardo and Scher, {H. I.}",
year = "1995",
language = "English (US)",
volume = "13",
pages = "1384--1390",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC

AU - Sarkis, A. S.

AU - Bajorin, D. F.

AU - Reuter, V. E.

AU - Herr, H. W.

AU - Netto, G.

AU - Zhang -, Z. F.

AU - Schultz, P. K.

AU - Cordon-Cardo, C.

AU - Scher, H. I.

PY - 1995

Y1 - 1995

N2 - Purpose: This study sought to examine the prognostic role nuclear overexpression in muscle-invasive bladder cancer because of its correlation with progression of superficial bladder cancer. Patients and Methods: Ninety of 111 patients treated with neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) with a median follow-up duration of 5.8 years were evaluated. p53 nuclear overexpression was determined by immunohistochemistry on deparaffinized tissue sections. Patients were stratified into two groups according to the percent of tumor cells with positive nuclear reactivity. Overexpression was defined as tumors with ≥ 20% cells with positive nuclear reactivity and nonoverexpression as tumors with less than 20% reactivity. Results: Nuclear overexpression was observed in 47 patients and nonoverexpression in 43 patients. Patients whose tumors had p53 overexpression had a significantly higher proportion of cancer deaths. A multivariate analysis that evaluated the pretreatment variables p53 nuclear overexpression, age, sex, palpable mass, prechemotherapy tumor stage, performance status, ureteral obstruction, tumor size, multifocality, and grade showed that p53 overexpression had independent significance for survival (P = .001; relative risk ratio, 3.1). The impact of p53 overexpression on survival was predominantly in T2 and T3a tumors. Long-term survival was evident in seven of 17 patients (41%) with p53 overexpression versus 20 of 26 (77%) in whom p53 was not overexpressed (P = .007). Conclusion: p53 nuclear overexpression has independent prognostic value for survival in patients with invasive bladder cancer treated with neoadjuvant chemotherapy.

AB - Purpose: This study sought to examine the prognostic role nuclear overexpression in muscle-invasive bladder cancer because of its correlation with progression of superficial bladder cancer. Patients and Methods: Ninety of 111 patients treated with neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) with a median follow-up duration of 5.8 years were evaluated. p53 nuclear overexpression was determined by immunohistochemistry on deparaffinized tissue sections. Patients were stratified into two groups according to the percent of tumor cells with positive nuclear reactivity. Overexpression was defined as tumors with ≥ 20% cells with positive nuclear reactivity and nonoverexpression as tumors with less than 20% reactivity. Results: Nuclear overexpression was observed in 47 patients and nonoverexpression in 43 patients. Patients whose tumors had p53 overexpression had a significantly higher proportion of cancer deaths. A multivariate analysis that evaluated the pretreatment variables p53 nuclear overexpression, age, sex, palpable mass, prechemotherapy tumor stage, performance status, ureteral obstruction, tumor size, multifocality, and grade showed that p53 overexpression had independent significance for survival (P = .001; relative risk ratio, 3.1). The impact of p53 overexpression on survival was predominantly in T2 and T3a tumors. Long-term survival was evident in seven of 17 patients (41%) with p53 overexpression versus 20 of 26 (77%) in whom p53 was not overexpressed (P = .007). Conclusion: p53 nuclear overexpression has independent prognostic value for survival in patients with invasive bladder cancer treated with neoadjuvant chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0029063351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029063351&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 1384

EP - 1390

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -